Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine in Persistent or Recurrent Non-Squamous Cervical Cancer
NCT00006224Phase 2Terminated
- Sponsor
- GOG Foundation
- Start
- Sep 2000
- Primary completion
- Apr 2005
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in Cervical Cancer (CC), sponsored by GOG Foundation. Primary endpoints: Objective Response Rate and Toxicity. Started Sep 2000; status: terminated.
02
Drugs
gemcitabine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT00006224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006224.